KR100700963B1 - 켐토테신의 다당체 유도체를 함유하는 동결건조된 액상제제 - Google Patents
켐토테신의 다당체 유도체를 함유하는 동결건조된 액상제제 Download PDFInfo
- Publication number
- KR100700963B1 KR100700963B1 KR1020047016514A KR20047016514A KR100700963B1 KR 100700963 B1 KR100700963 B1 KR 100700963B1 KR 1020047016514 A KR1020047016514 A KR 1020047016514A KR 20047016514 A KR20047016514 A KR 20047016514A KR 100700963 B1 KR100700963 B1 KR 100700963B1
- Authority
- KR
- South Korea
- Prior art keywords
- glycyl
- group
- liquid formulation
- glycine
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JPJP-P-2002-00112864 | 2002-04-16 | ||
| JP2002112864 | 2002-04-16 | ||
| PCT/JP2003/004745 WO2003086471A2 (en) | 2002-04-16 | 2003-04-15 | Lyophilized and liquid preparations comprising a polysaccharide derivative of camptothecin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20050000516A KR20050000516A (ko) | 2005-01-05 |
| KR100700963B1 true KR100700963B1 (ko) | 2007-03-28 |
Family
ID=29243336
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020047016514A Expired - Fee Related KR100700963B1 (ko) | 2002-04-16 | 2003-04-15 | 켐토테신의 다당체 유도체를 함유하는 동결건조된 액상제제 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20050215485A1 (enExample) |
| EP (1) | EP1501549A2 (enExample) |
| JP (1) | JP3927954B2 (enExample) |
| KR (1) | KR100700963B1 (enExample) |
| CN (1) | CN100544769C (enExample) |
| AR (1) | AR039272A1 (enExample) |
| AU (1) | AU2003223120B2 (enExample) |
| BR (1) | BR0309283A (enExample) |
| CA (1) | CA2480425A1 (enExample) |
| HR (1) | HRP20040894A2 (enExample) |
| ME (1) | MEP31308A (enExample) |
| MX (1) | MXPA04010178A (enExample) |
| MY (1) | MY136696A (enExample) |
| NO (1) | NO20044964L (enExample) |
| PL (1) | PL371677A1 (enExample) |
| RS (1) | RS91204A (enExample) |
| RU (1) | RU2315623C2 (enExample) |
| TW (1) | TW200306314A (enExample) |
| UA (1) | UA77295C2 (enExample) |
| WO (1) | WO2003086471A2 (enExample) |
| ZA (1) | ZA200408008B (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2556254A1 (en) * | 2004-02-13 | 2005-08-25 | Kabushiki Kaisha Yakult Honsha | Aqueous solution preparation containing camptothecins |
| CA2562904C (en) | 2004-04-27 | 2013-07-02 | Wellstat Biologics Corporation | Cancer treatment using viruses and camptothecins |
| US7767200B2 (en) | 2005-07-14 | 2010-08-03 | Wellstat Biologics Corporation | Cancer treatment using viruses, fluoropyrimidines and camptothecins |
| JP2007260275A (ja) * | 2006-03-29 | 2007-10-11 | Transcutaneous Technologies Inc | イオントフォレーシス装置及びイオントフォレーシス投与用組成物 |
| BRPI1011753B8 (pt) | 2009-06-22 | 2021-05-25 | Wyeth Llc | conjugados imunogênicos de polissacarídeo capsular de staphylococcus aureus de sorotipos 5 e 8, seu uso e composições que os compreendem |
| MX343111B (es) | 2009-06-22 | 2016-10-25 | Wyeth Llc | Composiciones inmunogenicas de antigenos de staphylococcus aureus. |
| CN102764260B (zh) * | 2011-04-30 | 2014-07-30 | 正大天晴药业集团股份有限公司 | 一种喜树碱衍生物的药物组合物及其制备方法 |
| JP5983608B2 (ja) * | 2011-07-15 | 2016-09-06 | コニカミノルタ株式会社 | 溶解助剤を利用したリポソーム含有製剤およびその製造方法 |
| JP6012902B1 (ja) | 2014-12-26 | 2016-10-25 | 日本化薬株式会社 | カンプトテシン類高分子誘導体の医薬製剤 |
| EP3345654A4 (en) * | 2015-09-03 | 2019-05-08 | Nippon Kayaku Kabushiki Kaisha | PHARMACEUTICAL COMPOSITION COMPRISING A CAMPTOTHECINPOLYMER DERIVATIVE |
| WO2017053920A1 (en) | 2015-09-25 | 2017-03-30 | Zy Therapeutics Inc. | Drug formulation based on particulates comprising polysaccharide-vitamin conjugate |
| RU2018129760A (ru) | 2016-03-01 | 2020-04-01 | Ниппон Каяку Кабусики Кайся | Фармацевтический препарат, содержащий полимерное производное на основе камптотецина |
| CN109481691A (zh) * | 2018-11-20 | 2019-03-19 | 珠海天香苑生物科技发展股份有限公司 | 吉西他滨-羧甲基多糖共轭物、制备方法及其用途 |
| EP4438062A1 (en) * | 2021-11-26 | 2024-10-02 | Astellas Pharma Inc. | Indocyanine compound-containing solid pharmaceutical composition |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002005855A1 (fr) * | 2000-07-13 | 2002-01-24 | Daiichi Pharmaceutical Co., Ltd. | Compositions pharmaceutiques contenant des composes dds |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5340817A (en) * | 1987-04-14 | 1994-08-23 | Research Triangle Institute | Method of treating tumors with anti-tumor effective camptothecin compounds |
| ATE136898T1 (de) * | 1991-10-29 | 1996-05-15 | Glaxo Wellcome Inc | Wasserlösliche camptothecinderivate |
| SG50747A1 (en) * | 1995-08-02 | 1998-07-20 | Tanabe Seiyaku Co | Comptothecin derivatives |
| IT1282673B1 (it) * | 1996-02-23 | 1998-03-31 | Ist Naz Stud Cura Dei Tumori | Derivati della camptotecina e loro uso come agenti antitumorali |
| TW527183B (en) * | 1996-06-06 | 2003-04-11 | Daiichi Seiyaku Co | Drug complex |
| US6288072B1 (en) * | 1999-12-29 | 2001-09-11 | Monroe E. Wall | Camptothecin β-alanine esters with topoisomerase I inhibition |
| AR030207A1 (es) * | 2000-04-07 | 2003-08-13 | Daiichi Seiyaku Co | Composicion farmaceutica que contiene un derivado de camptotecina y procedimiento de preparacion de la misma |
| TWI313609B (en) * | 2001-08-21 | 2009-08-21 | Mitsubishi Tanabe Pharma Corp | Pharmaceutical composition for inhibiting the metastasis or preventing the recurrence of malignant tumor |
-
2003
- 2003-04-01 TW TW092107354A patent/TW200306314A/zh unknown
- 2003-04-09 AR ARP030101238A patent/AR039272A1/es unknown
- 2003-04-11 MY MYPI20031367A patent/MY136696A/en unknown
- 2003-04-15 AU AU2003223120A patent/AU2003223120B2/en not_active Ceased
- 2003-04-15 JP JP2003587152A patent/JP3927954B2/ja not_active Expired - Fee Related
- 2003-04-15 US US10/509,912 patent/US20050215485A1/en not_active Abandoned
- 2003-04-15 BR BR0309283-6A patent/BR0309283A/pt not_active IP Right Cessation
- 2003-04-15 RS YU91204A patent/RS91204A/sr unknown
- 2003-04-15 MX MXPA04010178A patent/MXPA04010178A/es active IP Right Grant
- 2003-04-15 UA UA20041109367A patent/UA77295C2/uk unknown
- 2003-04-15 CN CNB038082292A patent/CN100544769C/zh not_active Expired - Fee Related
- 2003-04-15 ME MEP-313/08A patent/MEP31308A/xx unknown
- 2003-04-15 RU RU2004133349/15A patent/RU2315623C2/ru not_active IP Right Cessation
- 2003-04-15 KR KR1020047016514A patent/KR100700963B1/ko not_active Expired - Fee Related
- 2003-04-15 EP EP03719110A patent/EP1501549A2/en not_active Withdrawn
- 2003-04-15 WO PCT/JP2003/004745 patent/WO2003086471A2/en not_active Ceased
- 2003-04-15 CA CA002480425A patent/CA2480425A1/en not_active Abandoned
- 2003-04-15 PL PL03371677A patent/PL371677A1/xx not_active Application Discontinuation
- 2003-04-15 HR HR20040894A patent/HRP20040894A2/xx not_active Application Discontinuation
-
2004
- 2004-10-05 ZA ZA200408008A patent/ZA200408008B/en unknown
- 2004-11-15 NO NO20044964A patent/NO20044964L/no not_active Application Discontinuation
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002005855A1 (fr) * | 2000-07-13 | 2002-01-24 | Daiichi Pharmaceutical Co., Ltd. | Compositions pharmaceutiques contenant des composes dds |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2003223120A2 (en) | 2003-10-27 |
| RU2315623C2 (ru) | 2008-01-27 |
| CA2480425A1 (en) | 2003-10-23 |
| MY136696A (en) | 2008-11-28 |
| NO20044964L (no) | 2004-11-15 |
| UA77295C2 (en) | 2006-11-15 |
| TW200306314A (en) | 2003-11-16 |
| AU2003223120B2 (en) | 2006-10-05 |
| AU2003223120A1 (en) | 2003-10-27 |
| WO2003086471A3 (en) | 2004-04-15 |
| CN100544769C (zh) | 2009-09-30 |
| US20050215485A1 (en) | 2005-09-29 |
| MXPA04010178A (es) | 2005-06-08 |
| RU2004133349A (ru) | 2005-05-27 |
| HRP20040894A2 (en) | 2005-10-31 |
| JP2005523329A (ja) | 2005-08-04 |
| KR20050000516A (ko) | 2005-01-05 |
| CN1646172A (zh) | 2005-07-27 |
| BR0309283A (pt) | 2005-02-15 |
| RS91204A (sr) | 2006-12-15 |
| AR039272A1 (es) | 2005-02-16 |
| MEP31308A (en) | 2010-10-10 |
| WO2003086471A2 (en) | 2003-10-23 |
| EP1501549A2 (en) | 2005-02-02 |
| PL371677A1 (en) | 2005-06-27 |
| JP3927954B2 (ja) | 2007-06-13 |
| ZA200408008B (en) | 2005-06-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101502533B1 (ko) | 우수한 안정성을 갖는 택산 유도체 함유 주사제용동결건조 조성물 및 이의 제조방법 | |
| KR100942399B1 (ko) | Ｅｇｆ 수용체에 대한 항체를 함유하는 동결건조된 제제 | |
| KR100700963B1 (ko) | 켐토테신의 다당체 유도체를 함유하는 동결건조된 액상제제 | |
| US11759497B2 (en) | Daptomycin formulations | |
| JP2002363097A (ja) | 安定化された凍結乾燥型医薬組成物 | |
| EA036982B1 (ru) | Способ получения лиофилизированной фармацевтической композиции, содержащей митомицин с | |
| RU2345772C2 (ru) | Лиофилизированные композиции cci-779 | |
| JP2006137678A (ja) | インターロイキン−２組成物 | |
| JP4142149B2 (ja) | バンコマイシンの凍結乾燥製剤 | |
| CZ20023969A3 (cs) | Farmaceutická forma pro podávání peptidů, způsoby její výroby a použití | |
| JPH05331071A (ja) | カルシトニン遺伝子関連ペプチド類の凍結乾燥組成物および安定化法 | |
| HU217806B (hu) | Eljárás polimerhez kötött antraciklin-glikozidokat tartalmazó gyógyszerkészítmények előállítására | |
| WO2008023807A1 (fr) | Composition pharmaceutique stabilisée | |
| KR20050013612A (ko) | 올리고펩티드 및 에테르화된 시클로덱스트린을 포함하는액상 제제 | |
| CA2809646C (en) | 5.alpha.-androstane-3.beta.,5,6.beta.-triol injection and preparation method therefor | |
| AU2020311050B2 (en) | Stable formulations of recombinant proteins | |
| EP1310254A1 (en) | Medicinal compositions containing camptothecin derivative and ph regulating agent | |
| EA026064B1 (ru) | Твердая фармацевтическая композиция, полученная с помощью предварительной стадии замораживания и стадии лиофилизации | |
| JPH08231398A (ja) | 凍結乾燥製剤 | |
| JPWO2000051626A1 (ja) | 化学修飾ｇ−ｃｓｆ製剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| A201 | Request for examination | ||
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| PN2301 | Change of applicant |
St.27 status event code: A-5-5-R10-R13-asn-PN2301 St.27 status event code: A-5-5-R10-R11-asn-PN2301 |
|
| PN2301 | Change of applicant |
St.27 status event code: A-5-5-R10-R13-asn-PN2301 St.27 status event code: A-5-5-R10-R11-asn-PN2301 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-5-5-R10-R18-oth-X000 |
|
| FPAY | Annual fee payment |
Payment date: 20100204 Year of fee payment: 4 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 4 |
|
| LAPS | Lapse due to unpaid annual fee | ||
| PC1903 | Unpaid annual fee |
St.27 status event code: A-4-4-U10-U13-oth-PC1903 Not in force date: 20110323 Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE |
|
| PC1903 | Unpaid annual fee |
St.27 status event code: N-4-6-H10-H13-oth-PC1903 Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE Not in force date: 20110323 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-5-5-R10-R18-oth-X000 |
|
| PN2301 | Change of applicant |
St.27 status event code: A-5-5-R10-R13-asn-PN2301 St.27 status event code: A-5-5-R10-R11-asn-PN2301 |